Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-masked, Vehicle-controlled, Parallel Group Phase III Study of the Efficacy and Safety of a Single Sub-conjunctival Injection of XG-102 for the Reduction of Post-cataract Surgery Intraocular Inflammation
Conditions
Interventions
XG-102
Placebo
Locations
1
United States
Garden Grove, California, United States
Start Date
September 1, 2014
Primary Completion Date
December 1, 2015
Completion Date
December 1, 2015
Last Updated
January 24, 2017
NCT06346132
NCT07482709
NCT07351968
NCT06946290
NCT07041736
NCT07327931
Lead Sponsor
Xigen SA
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions